Pharmaceutical Tablets

Product Details:

Infliximab is a monoclonal antibody used as an immunosuppressive agent in the treatment of various autoimmune diseases. It is a chimeric monoclonal antibody that targets and inhibits tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in systemic inflammation.

Infliximab is indicated for the treatment of:

• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Plaque psoriasis
• Crohn's disease (both adult and pediatric)
• Ulcerative colitis (both adult and pediatric)

Infliximab binds to TNF-alpha, preventing it from interacting with its receptors on the surface of cells. This inhibits the inflammatory processes driven by TNF-alpha, reducing the symptoms and progression of autoimmune diseases.

Infliximab is administered via intravenous (IV) infusion. The dosage and frequency depend on the specific condition being treated:

• Rheumatoid arthritis: 3 mg/kg at 0, 2, and 6 weeks, then every 8 weeks, in combination with methotrexate.
• Ankylosing spondylitis: 5 mg/kg at 0, 2, and 6 weeks, then every 6 weeks.
• Psoriatic arthritis: 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks.
• Plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks.
• Crohn's disease (adult): 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks.
• Crohn's disease (pediatric): 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks.
• Ulcerative colitis (adult): 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks.
• Ulcerative colitis (pediatric): 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks.

Common side effects include:

• Infusion-related reactions (fever, chills, itching, rash)
• Upper respiratory infections
• Headache
• Abdominal pain
• Nausea
• Sinusitis

Serious side effects may include:

• Severe infections (e.g., tuberculosis, sepsis)
• Hepatitis B reactivation
• Heart failure
• Blood disorders (e.g., pancytopenia, leukopenia)
• Malignancies (e.g., lymphoma)
• Hepatotoxicity
• Autoimmune reactions (e.g., lupus-like syndrome)

• Known hypersensitivity to infliximab, murine proteins, or any of its excipients.
• Moderate to severe heart failure.
• Use with caution in patients with chronic infections, a history of recurrent infections, or underlying conditions that may predispose them to infections.
• Screen for latent tuberculosis before initiating treatment; treat latent tuberculosis prior to starting infliximab.
• Monitor for signs of infection during and after treatment.

• Live vaccines: Concurrent administration with live vaccines is not recommended due to increased risk of infections.
• Immunosuppressants: Caution with concurrent use of other immunosuppressive agents, as it may increase the risk of infections.

• Pregnancy: Classified as Category B. There are no adequate and well-controlled studies in pregnant women. Infliximab should be used during pregnancy only if clearly needed.
• Breastfeeding: Infliximab is excreted in human milk in low concentrations. The effects on the nursing infant are unknown. A decision should be made whether to discontinue breastfeeding or discontinue the drug.
• Pediatric Use: Safety and efficacy for pediatric Crohn's disease and ulcerative colitis have been established, but not for other conditions.
• Elderly Patients: Use with caution in elderly patients, who may be more susceptible to infections.

Product Details:

• Each film coated tablet contains:
• Tenofovir Disoproxil Fumarate IP 300 mg.
• Lamimvudine IP 300 mg.
• Efavirenz IP 600 mg.
• Colour: Titanium dioxide IP

Product Details:

• Each film coated tablet contains:
• Leucovorin calcium I.P.
• Equivalent to 
• Leucovorin 15 mg.
• Excipients  .q.s.
• Colour:Titanium dioxide I.P.

Product Details:

• Each film Coated Tablet contains:
• Bictegravir sodium equivalent to Bictegravir 50 mg.
• Emtricitabine IP 200 mg.
• Tenofovir alafenamide 25 mg.
• Excipients q.s.
• Colour:Titanium Dioxide IP.
• Dosage: As directed by the physician.
• Store at a temperature not exceeding 30"c.

Product Details:

• Each film coated tablet contains:
• Efavirenz IP 600 mg.
• Emtricitabine IP 200 mg.
• Tenofovir disoproxil fumarate IP 300 mg.
• Colour:Titanium dioxide IP,and oxide of iron And black oxide of iron.
• Store protected from moisture,at a temperture not exceeding 30"c.
• Keep the container tightiy closed.
• Dosage: As directed by the physician.

Product Details:

Descriptions. Rituximab injection is used alone or together with other medicines to treat a type of cancer called non-Hodgkin's lymphoma (NHL). It is also used in combination with other cancer medicines to treat mature B-cell non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-AL).

Product Details:

• Each uncoated tablet contains:
•  Abiraterone Acetate IP 500 mg.
• Excipients q.s.
• Dosage :
• As directed by the physician

Product Details:

• Each film-coated tablet contains.
• Efavirenz IP 600 mg.
• Emtricitabine IP 200 mg.
• Tenofovir disoproxil Fumarate IP 300 mg.
• Colours: Red oxide of iron,
• yellow oxide of iron and titanium dioxide IP.

Product Details:

• Each film coated tablet contains: 
• Tenofovir disoproxil fumarate IP 300 mg.
• (eq. to tenofovir disoproxil 245 mg)
• Lamivudine IP 300 mg.
• Efavirena IP 600 mg.
• Excipients q.s.
• Colours: Ferric oxide USP-NF yellow and titanium dioxide IP
• Dosage: As Directed by the physician.

Product Details:

• Composition:
• Each film coated tablet contains:
• Tofacitinib Citrate .
• Equivatent to tofacitinib 5 mg.
• Excipients qs.
• Colour:Titanium dioxide IP. 

Product Details:

• each film-coated tablet containe:
• Tenofovir Alafenamide fumarate IP equivalent to.
• Tenofovir Alafenamide 25 mg.
• Excipients .q.s.
• Colours:Ferric oxide USP-NF red.
• Ferrosoferric oxide USF-NF and titanium dioxide IP.
•  

Product Details:

• Each film coated tablet contains:
• Tenofovir alafenamide fumarate IP
• equivalent to tenofovir alafenamide 25 mg .
• Colour: Titanium dioxide IP.
• do not store above 30"c. Store in the original container. Protect from moisture.
• Dosage: As directed by gastroenterologist/hepatologist.
• See package insert for dosage and administration.

Product Details:

• Each film coated tablet contains:
• Cinacaicet 30 mg.
• Colours: Ferric oxide yellow USP-NF, indigo carmine aluminum lake titaniium dioxide IP.
• Excipients: Q.S.

Product Details:

• Each film coated tablet contains:
• Sofosbuvir 400 mg.
• Velpatasvir 100 mg.
• Colours: Titanium dioxide I.P abd brilliant blue FCF.

Product Details:

• Anastrozole is a type of hormone treatment. It works by lowering the levels of oestrogen hormones in your body. It is mainly prescribed for women who have been through the menopause and have a type of cancer called hormone-dependent breast cancer.

Product Details:

• Dosage as directed by the doctor.
• Store protected from light and moisture at a temperature not exceeding 30"c.
• Refer pack insert for further details.
• Keep out of reach of children.
• Each film coated table contains:
• Entecavir monohydrate IP.
• Equivalent to entecavir 0.5mg.
• Excipients q.s.
• Colour Titanium dioxide IP .

Product Details:

• Each film coated tablet contains:
• Sofosbuvir  400 mg.
• Velpatasvir  100 mg.
• ERxcipients q.s.
• Colours:Indigo carmine aluminum lake, brilliant blue FCF aluminum lake and titanium dioxide IP.
• Store protected from moisture, at a temperature not exceeding 30"C.

Product Details:

Rucaparib is an oral medication used in cancer treatment, particularly for ovarian cancer and other cancers associated with BRCA mutations. It belongs to a class of drugs known as PARP inhibitors.

Rucaparib tablets are indicated for:

• Treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
• Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Rucaparib inhibits the enzyme poly (ADP-ribose) polymerase (PARP). PARP is involved in DNA repair, and by inhibiting this enzyme, rucaparib prevents cancer cells from repairing their DNA, leading to cell death, especially in cancer cells with BRCA mutations that already have compromised DNA repair mechanisms.

• The recommended dose of rucaparib is 600 mg (two 300 mg tablets) taken orally twice daily, with or without food.
• Treatment should continue until disease progression or unacceptable toxicity occurs.

Common side effects include:

• Nausea
• Fatigue
• Vomiting
• Anemia
• Abdominal pain
• Dysgeusia (distorted sense of taste)
• Decreased appetite
• Constipation
• Diarrhea
• Thrombocytopenia (low platelet count)
• Elevated liver enzymes (AST/ALT)

Serious but less common side effects may include:

• Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)
• Severe bone marrow suppression
• Liver toxicity
• Severe hypersensitivity reactions

• Hypersensitivity to rucaparib or any of its components.
• Use with caution in patients with a history of myelodysplastic syndrome or acute myeloid leukemia.
• Monitor blood counts and liver function tests regularly.
• Assess for signs of bone marrow suppression.

• Rucaparib is primarily metabolized by the enzyme CYP2D6 and inhibits several cytochrome P450 enzymes (including CYP1A2, CYP2C19, and CYP3A4). Caution should be exercised when rucaparib is administered with drugs that are substrates or inhibitors/inducers of these enzymes, as interactions can alter the effectiveness or toxicity of either rucaparib or the co-administered drugs.

• Pregnancy: Rucaparib can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment and for six months following the last dose.
• Breastfeeding: It is not known if rucaparib is excreted in human milk. Women should not breastfeed during treatment with rucaparib and for two weeks after the final dose.
• Renal Impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment. The pharmacokinetics in patients with severe renal impairment or end-stage renal disease have not been studied.
• Hepatic Impairment: No dose adjustment is necessary for patients with mild hepatic impairment. The pharmacokinetics in patients with moderate to severe hepatic impairment have not been studied.

Product Details:

• Each gastro-resistant tablet contains 100 mg of posaconazole. For the full list of excipients, see section 6.1. 3. Pharmaceutical form. Gastro-resistant tablet.

Product Details:

Amphotericin B injection is an antifungal medication used to treat serious fungal infections. It is often administered in a hospital setting due to its potent effects and potential side effects. Here is a detailed overview:

1. Systemic Fungal Infections: Amphotericin B is primarily used for severe systemic fungal infections such as:

   • Aspergillosis
   • Candidiasis
   • Cryptococcosis
   • Histoplasmosis
   • Blastomycosis
   • Coccidioidomycosis

2. Leishmaniasis: It is also used to treat visceral leishmaniasis, a parasitic disease.

Amphotericin B works by binding to ergosterol, a key component of fungal cell membranes. This binding creates pores in the membrane, leading to leakage of cell contents and ultimately cell death.

• Intravenous Injection: Amphotericin B is usually given by slow intravenous infusion. The dosage and duration depend on the type and severity of the infection, as well as the patient's response to the treatment.

• Conventional Amphotericin B (Fungizone)
• Liposomal Amphotericin B (AmBisome)
• Amphotericin B Lipid Complex (Abelcet)
• Amphotericin B Cholesteryl Sulfate Complex (Amphotec)

The lipid formulations are generally preferred due to their lower toxicity profiles.

• Common:

  • Fever and chills
  • Nausea and vomiting
  • Headache

• Serious:

  • Nephrotoxicity (kidney damage)
  • Hypokalemia (low potassium levels)
  • Hypomagnesemia (low magnesium levels)
  • Anemia
  • Infusion reactions

Patients receiving Amphotericin B need close monitoring due to its potential side effects. This includes:

• Regular kidney function tests
• Electrolyte levels (potassium and magnesium)
• Complete blood count (CBC)
• Liver function tests

• Renal Impairment: Dose adjustments may be necessary.
• Electrolyte Imbalance: Pre-existing imbalances should be corrected before starting treatment.
• Pregnancy and Breastfeeding: It should be used only if clearly needed and after assessing the risks and benefits.

Amphotericin B is a crucial drug for treating severe fungal infections, particularly in immunocompromised patients. Despite its potential for serious side effects, careful monitoring and the use of lipid formulations can mitigate some of these risks, making it a valuable option in antifungal therapy.

Additional Information:

• Delivery Time: Hyderabad up to 2hr non Hyderabad 24 hr to 48 hrs
• Packaging Details: Ambilon 50 mg injetion ( amphotericin B Liposome Injecton 50 mg ) manufactured&marketed by celon laboratories.

Product Details:

• VORIER 200MG TABLETS (VORICONAZOLE TABLETS IP 200MG)